CBS reopened its probe into sexual assault allegations against 'Matlock' actor David Del Rio, who was fired in October ...
Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...
The Windows Start menu is getting its first major redesign since 2021 and will be rolled out to everyone with the November 11 Patch Tuesday update. The Start menu is now scrollable, so you can move ...
Novartis announced positive results from V-DIFFERENCE, a phase IV study evaluating Leqvio (inclisiran) compared to placebo, both administered on top of individually optimized lipid-lowering therapy ...
12:54, Sun, Aug 31, 2025 Updated: 12:57, Sun, Aug 31, 2025 A twice-yearly jab that combats cholesterol could revolutionise heart care, according to its creator. The drug, Leqvio, also known as ...
Novartis AG (NYSE:NVS) is one of the 11 Best Annual Dividend Stocks to Buy According to Hedge Funds. The company’s positive outlook strengthens with new updates on ianalumab and Leqvio. Novartis AG ...
A cholesterol-busting jab that is administered twice a year has the potential to transform heart care, according to its developer. It comes as new trial data suggests Leqvio, also known as inclisiran ...
V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C) goals early with reduced muscle pain 1 85% ...
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...
A cholesterol-busting jab that is administered twice a year has the potential to transform heart care, according to its developer. It comes as new trial data suggests Leqvio, also known as inclisiran ...
A groundbreaking cholesterol-lowering injection, administered just twice annually, could revolutionise heart disease management, its developers have claimed. New trial data for Leqvio, also known as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback